Targeted therapies in breast cancer: New challenges to fight against resistance

WORLD JOURNAL OF CLINICAL ONCOLOGY - Tập 8 Số 2 - Trang 120 - 2017
Viviana Masoud1,2, Gilles Pagès1,2
1Director of Research INSERM, University Nice Sophia Antipolis, Institute for Research on Cancer and Aging of Nice CNRS UMR7284/INSERM U 1081, Centre Antoine Lacassagne 33 Avenue de Valombrose, 06189 Nice, France.
2University Nice Sophia Antipolis, Institute for Research on Cancer and Aging of Nice CNRS UMR7284/INSERM U 1081, 06189 Nice, France

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/j.clbc.2015.09.004

10.1001/jamaoncol.2015.6478

10.1093/annonc/mdw150

10.1158/1078-0432.CCR-15-1881

10.1146/annurev-med-042513-015127

10.1053/j.seminoncol.2015.09.029

10.1001/jamaoncol.2015.2286

10.1016/j.tips.2015.08.009

10.1186/s12916-015-0369-5

10.1007/s10549-014-3250-x

10.1159/000433622

10.1200/JCO.2013.54.0948

Akin S, Babacan T, Sarici F, Altundag K. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors. J BUON 2014;19:42-46.

10.1200/JCO.2012.44.7912

10.2217/fon.12.95

10.1016/j.ejca.2011.12.007

10.1016/j.ctrv.2010.07.004

10.1038/nrclinonc.2010.122

10.1016/S0960-9776(09)70271-1

10.2325/jbcs.971

10.1200/JCO.2005.03.3845

10.1007/s10549-010-1293-1

10.1038/35052073

10.1530/ERC-16-0121

10.4155/fmc.15.93

10.1146/annurev-med-070909-182917

10.1186/s13058-015-0561-8

10.1093/annonc/mdp492

10.1530/ERC-14-0447

10.1016/j.ctrv.2015.08.001

10.1016/j.breast.2015.06.002

10.1016/j.mce.2013.03.023

10.1007/s00432-013-1494-1

10.2217/fon.12.86

10.1615/CritRevOncog.v17.i1.20

10.3389/fonc.2013.00250

10.1056/NEJM200103153441101

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.

10.1056/NEJMoa1413513

10.1007/s40259-016-0162-9

10.1172/JCI57152

10.1016/j.clbc.2014.10.006

10.1056/NEJMoa072113

10.1159/000405017

10.1016/j.molcel.2015.11.006

10.1111/bph.13211

10.1053/j.seminoncol.2015.09.028

10.4103/0253-7613.81497

10.1016/j.tranon.2016.01.001

10.1002/jcb.25590

10.1097/CAD.0000000000000354

10.2147/OTT.S97664

Dey N, Williams C, Leyland-Jones B, De P. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res 2015;7:733-750.

10.1111/bcp.12958

10.2174/138920101609150715141545

Lee JJ, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med 2015;12:342-354.

10.1093/jnci/djv212

10.1093/annonc/mdq122

10.1200/JCO.2016.67.0182

10.1185/03007995.2013.775113

10.1056/NEJMoa1113216

10.1093/jnci/dju169

10.7314/APJCP.2016.17.4.1609

10.1038/nrclinonc.2016.35

10.2174/1381612822666160715132233

10.1016/j.jsbmb.2016.05.001

10.2174/1389450117666160601151039

10.1016/S1470-2045(16)00150-9

Tsiambas E, Ragos V, Lefas AY, Georgiannos SN, Rigopoulos DN, Georgakopoulos G, Stamatelopoulos A, Grapsa D, Syrigos K. Molecular assays in detecting EGFR gene aberrations: an updated HER2-dependent algorithm for interpreting gene signals; a short technical report. J BUON 2016;21:512-515.

10.1073/pnas.1537685100

10.1016/S0014-4827(02)00099-X

10.1007/s12282-015-0587-x

10.4161/cbt.11.9.15045

10.1186/1471-2407-14-134

10.1186/bcr2868

10.1186/s13058-015-0569-0

10.1186/1476-4598-13-242

10.1186/1475-2867-13-97

10.1093/hmg/ddr390

10.1038/onc.2010.168

10.1158/0008-5472.CAN-08-4238

10.5306/wjco.v5.i3.323

10.1089/jir.2013.0140

10.1093/annonc/mdm181

10.1200/JCO.2006.09.1611

10.1016/j.breast.2015.03.001

10.18632/oncotarget.10195

10.1016/j.ctrv.2012.12.002

10.1038/nm.4120

10.1158/1078-0432.CCR-06-1560

10.1158/2159-8290.CD-14-0788

10.1016/j.cell.2011. 02.013

10.2174/1568009611313020008

10.1186/1756-0500-7-397

10.1186/1476-4598-13-105

10.1158/1535-7163.MCT-11-0754

10.1186/bcr3650

10.1038/nature11249

10.1158/1078-0432.CCR-14-2728

10.1016/j.yexcr.2005.11.012

10.1038/nm0603-669

10.1016/j.yexcr.2005.11.024

10.1016/j.molcel.2008.04.009

Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 2001;52:43-47.

10.1186/bcr1796

10.1001/jama.2011.51

10.1177/1947601909356574

10.1016/j.biochi.2013.03.002

10.1093/annonc/mds187

10.1158/1078-0432.CCR-12-2243

10.1186/s13058-015-0590-3

10.1186/2045-824X-6-12

10.1093/annonc/mdp062

10.1056/NEJMoa1011418

Mittendorf EA, Peoples GE. Injecting Hope--A Review of Breast Cancer Vaccines. Oncology (Williston Park) 2016;30:475-481, 485.

10.1158/2326-6066.CIR-13-0127

10.1111/bjh.12380

Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol 2014;4:385.

10.1158/1538-7445.SABCS15-PD5-06